Search research articles
Contact Us
Filters
Showing results (161-170 of 168) with videos related to
Page
of 17
Sort By:
You have reached the last page of results.
This site can display upto 168 results.
ESMO Open
|
August 30, 2024
A phase II study of tepotinib in patients with advanced solid cancers harboring MET exon 14 skipping mutations or amplification (KCSG AL19-17)
E J Kang, Y Yang, S Lee, et al.
ESMO Open
|
March 20, 2025
Corrigendum to "A phase II study of tepotinib in patients with advanced solid cancers harboring MET exon 14 skipping mutations or amplification (KCSG AL19-17)": [ESMO Open 9 (2024) 103668]
E J Kang, Y Yang, S Lee, et al.
Cell Death and Differentiation
|
February 28, 2015
The LIM-only transcription factor LMO2 determines tumorigenic and angiogenic traits in glioma stem cells
S-H Kim, E-J Kim, M Hitomi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 2, 2012
Extranodal natural killer/T-cell lymphoma from skin or soft tissue: suggestion of treatment from multinational retrospective analysis
H K Ahn, C Suh, S S Chuang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 28, 2017
Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/II NK/T-cell lymphoma
Y L Kwong, S J Kim, E Tse, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 5, 2020
A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial<sup>☆</sup>
S H Park, D H Lim, T S Sohn, et al.
ESMO Open
|
September 18, 2025
Identifying predictive markers of head and neck squamous cell carcinoma in an umbrella trial (KCSG HN 15-16 TRIUMPH trial)
S Hwang, M H Hong, S H Shin, et al.
ESMO Open
|
July 8, 2026
Phase II study of trastuzumab-pkrb plus gedatolisib in patients with HER2-positive metastatic breast cancer who progressed after two or more HER2-directed therapies
J W Kim, Y H Park, S Lee, et al.
Page
of 17
Search research articles
Search
Showing results (161-170 of 168) with videos related to
Sort By:
Page
of 17
You have reached the last page of results.
This site can display upto 168 results.
ESMO Open
|
August 30, 2024
A phase II study of tepotinib in patients with advanced solid cancers harboring MET exon 14 skipping mutations or amplification (KCSG AL19-17)
E J Kang, Y Yang, S Lee, et al.
ESMO Open
|
March 20, 2025
Corrigendum to "A phase II study of tepotinib in patients with advanced solid cancers harboring MET exon 14 skipping mutations or amplification (KCSG AL19-17)": [ESMO Open 9 (2024) 103668]
E J Kang, Y Yang, S Lee, et al.
Cell Death and Differentiation
|
February 28, 2015
The LIM-only transcription factor LMO2 determines tumorigenic and angiogenic traits in glioma stem cells
S-H Kim, E-J Kim, M Hitomi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 2, 2012
Extranodal natural killer/T-cell lymphoma from skin or soft tissue: suggestion of treatment from multinational retrospective analysis
H K Ahn, C Suh, S S Chuang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 28, 2017
Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/II NK/T-cell lymphoma
Y L Kwong, S J Kim, E Tse, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 5, 2020
A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial<sup>☆</sup>
S H Park, D H Lim, T S Sohn, et al.
ESMO Open
|
September 18, 2025
Identifying predictive markers of head and neck squamous cell carcinoma in an umbrella trial (KCSG HN 15-16 TRIUMPH trial)
S Hwang, M H Hong, S H Shin, et al.
ESMO Open
|
July 8, 2026
Phase II study of trastuzumab-pkrb plus gedatolisib in patients with HER2-positive metastatic breast cancer who progressed after two or more HER2-directed therapies
J W Kim, Y H Park, S Lee, et al.
Page
of 17